zolbetuximab
astellas,leap therapeutics
[]
a few thoughts on $alpmy zolbetuximab data, from last night's #gi23 presentation: how much of this market might claudin18.2-positivity account for? well, spotlight assessed 2,244 patients, and deemed 865 of them (38.5%) to be claudin18.2 moderate to strong. $lptx 
Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today.